Bardoxolone methyl
「Bardoxolone methyl」熱門搜尋資訊
「Bardoxolone methyl」文章包含有:「Bardoxolonemethyl」、「Bardoxolonemethyl(CDDO」、「Bardoxolonemethyl(RTA402,甲基巴多索隆)」、「BardoxoloneMethyl」、「Bardoxolonemethylanalogattenuatesproteinuria」、「BardoxoloneMethylandKidneyFunctioninCKDwithType...」、「BardoxoloneMethylinType2DiabetesandStage4...」、「Bardoxolonemethyl:Uses」、「FDARejectsBardoxoloneMethylForChronicKidney...」
查看更多Bardoxolone methyl
https://en.wikipedia.org
Bardoxolone methyl is an experimental and orally-bioavailable semi-synthetic triterpenoid, based on the scaffold of the natural product oleanolic acid.
Bardoxolone methyl (CDDO
https://www.ncbi.nlm.nih.gov
As a multifunctional agent, CDDO-Me has improved the renal function in patients with chronic kidney disease associated with type 2 diabetes.
Bardoxolone methyl (RTA 402,甲基巴多索隆)
https://www.medchemexpress.cn
Bardoxolone methyl (NSC 713200; RTA 402; CDDO Methyl ester) 是一种合成的三萜类化合物,具有潜在的抗肿瘤和抗炎活性,作为Nrf2 通路的激活剂和NF-κB 途径的抑制剂。
Bardoxolone Methyl
https://www.sciencedirect.com
Bardoxolone methyl is a semisynthetic triterpene, which promotes antioxidant response and inhibits pro-inflammatory signals through activating nuclear factor ...
Bardoxolone methyl analog attenuates proteinuria
https://pubmed.ncbi.nlm.nih.go
Multiple clinical studies have shown that bardoxolone methyl, a potent activator of nuclear factor erythroid 2-related factor 2 (Nrf2), is effective in ...
Bardoxolone Methyl and Kidney Function in CKD with Type ...
https://www.nejm.org
Bardoxolone methyl, an oral antioxidant inflammation modulator, has shown efficacy in patients with CKD and type 2 diabetes in short-term ...
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 ...
https://www.nejm.org
Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death ...
Bardoxolone methyl: Uses
https://go.drugbank.com
It is a novel targeted cancer therapy with a unique mechanism of action. It exploits fundamental physiological differences between cancerous and ...
FDA Rejects Bardoxolone Methyl For Chronic Kidney ...
https://www.hcplive.com
The complete response letter from the FDA cited a lack of effectiveness in slowing the loss of kidney function in patients with Alport syndrome.